Multiple System Atrophy Treatment Algorithm, Clinical Trials and Pipeline Analysis, 2025 | Theravance Biopharma, H. Lundbeck A/S, Yoda Pharmaceuticals, Alterity Therapeutics, CORESTEM, Inc., ProMIS Neurosciences

Multiple system atrophy Pipeline constitutes 12+ key companies continuously working towards developing 12+ Multiple system atrophy treatment therapies, analyzes DelveInsight.

Multiple system atrophy Disease Overview:

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting approximately 15,000 to 50,000 Americans of all racial backgrounds. Its exact cause is unknown, and most cases occur randomly (sporadic).

MSA impacts both the central nervous system (which controls movement) and the autonomic nervous system (which regulates involuntary functions like blood pressure and digestion).

There are two main types of MSA, based on the dominant symptoms:

- MSA-P (Parkinsonian type): Resembles Parkinson's disease with symptoms such as slow movement, stiffness, tremors, and balance issues, alongside autonomic dysfunction like urinary or digestive problems.
- MSA-C (Cerebellar type): Involves coordination and balance difficulties (ataxia), speech and swallowing challenges, and irregular eye movements.

Both types reflect the complexity and severity of the condition.

"Multiple system atrophy Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple system atrophy Therapeutics Market.

Request for a Multiple system atrophy pipeline sample report @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Multiple system atrophy Pipeline Report

In March 2025, the FDA granted Orphan Drug Designation to exidavnemab, a monoclonal antibody developed by BioArctic, for the treatment of MSA. This designation provides incentives to encourage the development of therapies for rare diseases.
In February 2025, the FDA granted Fast Track status to amlenetug, a monoclonal antibody targeting extracellular α-synuclein, intended to prevent its aggregation and promote immune-mediated clearance.
In April 2024, amlenetug received Orphan Drug Designation from the FDA, recognizing its potential in treating a rare disease with significant unmet medical need.
DelveInsight's Multiple system atrophy pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Multiple system atrophy treatment.
Key Multiple system atrophy companies such as Theravance Biopharma, H. Lundbeck A/S, Yoda Pharmaceuticals, Alterity Therapeutics, CORESTEM, Inc., ProMIS Neurosciences, and others are evaluating new drugs for Multiple system atrophy to improve the treatment landscape.
Promising Multiple system atrophy therapies are Ampreloxetine, YA-101, ATH434, and others.

Multiple system atrophy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Multiple system atrophy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple system atrophy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple system atrophy market.

Request for detailed insights into our Multiple system atrophy pipeline insights report @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple System Atrophy Emerging Drugs and Companies

Ampreloxetine: Theravance Biopharma

Ampreloxetine is an investigational, once-daily, long-acting norepinephrine reuptake inhibitor being developed to treat symptomatic neurogenic orthostatic hypotension (nOH) in people with multiple system atrophy (MSA). In Study 0170, MSA patients showed several promising outcomes, including increased norepinephrine levels, improved blood pressure regulation, significant and lasting symptom relief, and no signs of supine hypertension (high blood pressure while lying down).

YA-101: Yoda Pharmaceuticals
YA-101, developed by Yoda Pharmaceuticals, is a novel chemical entity (NCE) designed to treat neurodegenerative disorders by reducing neuroinflammation and promoting neural plasticity. It functions as a dual modulator, targeting both the GluN1 subunit of the NMDA receptor and the NLRP3 inflammasome, aiming to address conditions like Multiple System Atrophy (MSA), Alzheimer's disease, and schizophrenia. YA-101 is currently undergoing evaluation in a Phase II clinical trial for MSA patients.

ATH434: Alterity Therapeutics
Alterity's lead candidate, ATH434, is an oral therapy developed to prevent the buildup of harmful proteins linked to neurodegenerative diseases. Preclinical studies have shown that ATH434 can reduce α-synuclein pathology and help maintain neuronal function by normalizing iron levels in the brain. Acting as an iron chaperone, ATH434 holds strong potential for treating Parkinson's disease and related disorders like Multiple System Atrophy (MSA). It is currently being tested in a Phase II clinical trial for MSA patients.

Multiple system atrophy Companies

Around 12 or more key companies are actively working on developing therapies for Multiple System Atrophy (MSA). Among them, Theravance Biopharma stands out with its drug candidate currently in the most advanced stage of development - Phase III clinical trials.

Explore which key multiple system atrophy companies are working to develop novel therapies which will drive the market in the upcoming years @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Multiple system atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Multiple system atrophy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple system atrophy Therapies and Key Companies: Multiple system atrophy Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple system atrophy Pipeline Therapeutic Assessment
• Multiple system atrophy Assessment by Product Type
• Multiple system atrophy By Stage
• Multiple system atrophy Assessment by Route of Administration
• Multiple system atrophy Assessment by Molecule Type

Download Multiple system atrophy Sample report to know in detail about the Multiple system atrophy treatment market @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Multiple system atrophy Current Treatment Patterns
4. Multiple system atrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple system atrophy Late-Stage Products (Phase-III)
7. Multiple system atrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple system atrophy Discontinued Products
13. Multiple system atrophy Product Profiles
14. Multiple system atrophy Key Companies
15. Multiple system atrophy Key Products
16. Dormant and Discontinued Products
17. Multiple system atrophy Unmet Needs
18. Multiple system atrophy Future Perspectives
19. Multiple system atrophy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Multiple system atrophy Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.